Viking Therapeutics Announces Clinical Hold on Phase 1b Trial of VK0214 in Patients with X-ALD
- Monday, January 24, 2022, 7:20
- PR Newswire
- Add a comment
SAN DIEGO, Jan. 24, 2022 /PRNewswire/ — Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its Phase 1b clinical trial of VK0214 in…
About the Author
admin has written 21717 stories on this site.